Genomic Testing for Localized Prostate Cancer

Where Do We Go From Here?

Stacy Loeb; Ashley E. Ross


Curr Opin Urol. 2017;27(5):495-499. 

In This Article


For men with localized prostate cancer making decisions about initial or second-line therapy, there are multiple commercially available genomic tests that can be ordered to provide additional prognostic information. The Prolaris, OncotypeDx, and genomic classifiers are available for biopsy tissue, and the Prolaris and genomic classifiers can be used after radical prostatectomy.